For Immediate Release: February 24, 2015

Mary Kuramoto
513-579-9911 x2523

Evan Stein, MD, PhD, of Medpace Reference Laboratory (MRL) to Present on the Latest Developments of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia at ASCPT

CINCINNATI, OH — (February 24, 2015) – Dr. Evan Stein, MRL Chief Scientific Officer and Director Emeritus of the Medpace Metabolic & Atherosclerosis Research Center will speak at the annual ASCPT meeting, March 3-7, 2015 in New Orleans. The session, “Development PCSK9 Inhibitors: A Paradigm Shift in the Treatment of Hypercholesterolemia,” will provide updates in the development of a new class of drugs, PCSK9 Inhibitors. These new compounds have been found to lower low-density lipoprotein cholesterol (LDL-C), offering hypercholesterolemia patients alternative treatments to a more traditional statin therapy.

Dr. Stein, a noted industry expert and pioneer in the development of lipid-lowering therapies, will update the audience on new directions for the treatment of hypercholesterolemia stemming from this new class of drugs. The symposia will take place Friday, March 6th from 10:30 am-12:30 pm within the Pharmacometrics and Pharmacokinetics (PMK) Biologics scientific section of the meeting.

About Evan Stein, MD, PhD.

Dr. Stein is the Chief Scientific Officer for Medpace Reference Laboratories. Dr. Stein has held a number of appointments to the NIH, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the NHLBI Program on Genetics in Hypertension. From 2006-2010, he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel. Dr. Stein is an accomplished researcher in the field of lipid metabolism with extensive publications in this field. He is an authority on the clinical treatment of hyperlipidemia, as well as on the laboratory measurements of lipid parameters. Dr. Stein consults with many pharmaceutical companies on the development programs for lipid-lowering drugs and participates in many Scientific Advisory Boards for these companies.


MRL is a full-service central laboratory with locations in the USA, Belgium, China, and Singapore. MRL uses state-of-the-art instrumentation and methods, which are identical at all MRL global sites. MRL provides production and shipping of specimen collection kits; formally correlated testing menus; customized reporting and delivery options to accommodate international requirements; long-term archival specimen storage; and appropriate quality assurance and is CAP accredited and has NGSP Level 1 and CDC Lipid Standardization Part III standardization. The Metabolic & Atherosclerosis Research Center is a phase 1 through 3 clinical site that specializes in design and conduct of trials of new lipid agents, especially in patients with inherited lipid disorders and children.



Medpace is a global full-service clinical research organization (CRO) providing Phase I-IV core development services for drug, biologic, and device programs. Medpace has strong experience supporting development programs across a number of therapeutic areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, neuroscience, regenerative medicine, gastrointestinal diseases, pediatrics, and orphan disease. With extensive medical expertise, and renowned regulatory affairs department, Medpace employs 2000 employees and has clinical trial experience in over 45 countries and 6 regions – North America, Europe, Asia Pacific, Latin America, Africa, and the Middle East. From feasibility, research site compatibility, safety, and logistics, Medpace brings efficiencies and operational excellence to both drug and device development programs. In addition, Medpace offers integrated imaging, central and bioanalytical lab capabilities, and clinical pharmacology through wholly-owned business units to provide cohesive, streamlined, and standardized trial management.

For more information visit the Medpace website at: